C-Reactive Protein

Trpković, Ana; Obradović, Milan; Petrovic, Nina; Davidovic, Radoslav; Sudar-Milovanović, Emina; Isenović, Esma R.

doi:10.1007/978-1-4614-6438-9_101542-1

Cited by 2 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have extensively examined the role of inflammation in the genesis and progression of CVDs [ 31 , 32 ]. However, new inflammatory biomarkers, such as C-reactive protein (CRP) [ 33 ], interleukins (IL) [ 34 ], tumour necrosis factor-alpha (TNF-α), and nitrotyrosine, have emerged in recent decades [ 30 ]. We must mention sirtuins (SIRT), micro RNAs (miRs), ST2 protein, apolipoprotein E protein, adiponectin, and others among these new biomarkers [ 30 ].…”

Section: Cardiovascular Disease (Cvds)mentioning

confidence: 99%

Role of Chemerin in Cardiovascular Diseases

et al. 2022

View full text Add to dashboard Cite

(1) Background: Obesity is closely connected to the pathophysiology of cardiovascular diseases (CVDs). Excess fat accumulation is associated with metabolic malfunctions that disrupt cardiovascular homeostasis by activating inflammatory processes that recruit immune cells to the site of injury and reduce nitric oxide levels, resulting in increased blood pressure, endothelial cell migration, proliferation, and apoptosis. Adipose tissue produces adipokines, such as chemerin, that may alter immune responses, lipid metabolism, vascular homeostasis, and angiogenesis. (2) Methods: We performed PubMed and MEDLINE searches for articles with English abstracts published between 1997 (when the first report on chemerin identification was published) and 2022. The search retrieved original peer-reviewed articles analyzed in the context of the role of chemerin in CVDs, explicitly focusing on the most recent findings published in the past five years. (3) Results: This review summarizes up-to-date findings related to mechanisms of chemerin action, its role in the development and progression of CVDs, and novel strategies for developing chemerin-targeting therapeutic agents for treating CVDs. (4) Conclusions: Extensive evidence points to chemerin’s role in vascular inflammation, angiogenesis, and blood pressure modulation, which opens up exciting perspectives for developing chemerin-targeting therapeutic agents for the treatment of CVDs.

show abstract

Section: Cardiovascular Disease (Cvds)mentioning

confidence: 99%

Role of Chemerin in Cardiovascular Diseases

et al. 2022

View full text Add to dashboard Cite

show abstract

“…CRP was first described as a serum protein capable of precipitating C-polysaccharide pneumococcal cell walls during the acute phase of infective conditions in the presence of calcium [ 26 – 28 ]. We know CRP belongs to a conserved protein family called pentraxins and has been identified in several organisms ranging from arthropods to humans [ 29 , 30 ]. Structurally, it is a 206 amino acid cyclic pentameric protein with five identical subunits noncovalently connected, with a molecular weight of ~23 kDa ( Figure 1 ) [ 31 ].…”

Section: Crpmentioning

confidence: 99%

Role of C-Reactive Protein in Diabetic Inflammation

Stanimirović

Radovanović

Banjac

et al. 2022

Mediators of Inflammation

Self Cite

View full text Add to dashboard Cite

Even though type 2 diabetes mellitus (T2DM) represents a worldwide chronic health issue that affects about 462 million people, specific underlying determinants of insulin resistance (IR) and impaired insulin secretion are still unknown. There is growing evidence that chronic subclinical inflammation is a triggering factor in the origin of T2DM. Increased C-reactive protein (CRP) levels have been linked to excess body weight since adipocytes produce tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6), which are pivotal factors for CRP stimulation. Furthermore, it is known that hepatocytes produce relatively low rates of CRP in physiological conditions compared to T2DM patients, in which elevated levels of inflammatory markers are reported, including CRP. CRP also participates in endothelial dysfunction, the production of vasodilators, and vascular remodeling, and increased CRP level is closely associated with vascular system pathology and metabolic syndrome. In addition, insulin-based therapies may alter CRP levels in T2DM. Therefore, determining and clarifying the underlying CRP mechanism of T2DM is imperative for novel preventive and diagnostic procedures. Overall, CRP is one of the possible targets for T2DM progression and understanding the connection between insulin and inflammation may be helpful in clinical treatment and prevention approaches.

show abstract

C-Reactive Protein

Cited by 2 publications

References 18 publications

Role of Chemerin in Cardiovascular Diseases

Role of Chemerin in Cardiovascular Diseases

Role of C-Reactive Protein in Diabetic Inflammation

Contact Info

Product

Resources

About